Rapid Screening Testing Reporting Guidance

Requirement Overview 

WAC 246-101-200, effective January 1, 2023, states an individual or entity including, but not limited to, health care providers and health care facilities, that conduct rapid screening tests for certain conditions (blood lead level testing, Hepatitis C (acute and chronic infection), HIV infection, or COVID-19) meets the definition of a laboratory under the chapter and must fulfill the reporting requirements outlined in WAC 246-101-201 through 246-101-230

Reporting Process 

Rapid screening test results for HIV must be submitted to the Office of Infectious Disease using one of the three reporting mechanisms: 

  1. Submit results via your organization's secure email
  2. Submit results via Managed File Transfer. If you do not have an MFT account with the Office of Infectious Disease, please request one via email
  3. Submit results via fax to 360-236-3470.

Rapid screening test results for Hepatitis C should be reported to the Local Health Jurisdiction (LHJ) of the client or patient's residence. DOH case report forms for hepatitis C may be used to report results. DOH-supported HCV screening programs should use the Minimum Required Fields case report form. Non-LHJ reporters should fill out any sections that do not state it is for LHJ use only.

Rapid screening test results for COVID-19 should be reported using the Point-of-Care test results process.   


Please contact OID Notifiable Conditions via email for additional questions about reporting Hepatitis C and HIV rapid screening test results.  

Please contact Blood Lead via email for questions about reporting Blood Lead rapid screening test results.